Back to News
Market Impact: 0.2
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Source: Business Wire
Healthcare & Biotech
Seaport Therapeutics, a PureTech-founded entity, dosed the first patient in its Phase 2a GlyphAgo trial for generalized anxiety disorder and sleep disturbance. The headline provides no trial results or additional details on enrollment, timing, or market response.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PRTC0.10
SPTX0.50
More News
- Seaport Therapeutics doses first patient in anxiety trial
- PureTech Health gets Panmure Liberum ‘buy' on value and cash returns
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results